donafenib   Click here for help

GtoPdb Ligand ID: 11830

Synonyms: CM-4307 | CM4307 | Sorafenib-d3 | Zepsun®
Compound class: Synthetic organic
Comment: Donafenib (CM-4307) is a deuterated derivative of the approved multikinase inhibitor sorafenib. Like sorafenib, it is orally active. Deuteration improves the stability of drug molecules thus extending half-life and increasing systemic exposure. This means that the effective drug dose may be shifted downward, with an associated improvement in tolerability. The medical formulation is donafenib tosylate.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 92.35
Molecular weight 464.09
XLogP 3.75
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(Nc1ccc(c(c1)C(F)(F)F)Cl)Nc1ccc(cc1)Oc1ccnc(c1)C(=O)NC([2H])([2H])[2H]
Isomeric SMILES C([2H])([2H])([2H])NC(=O)c1nccc(c1)Oc1ccc(cc1)NC(=O)Nc1cc(c(cc1)Cl)C(F)(F)F
InChI InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
1. Keam SJ, Duggan S. (2021)
Donafenib: First Approval.
Drugs, 81 (16): 1915-1920. [PMID:34591285]
2. Liu J, Li X, Zhang H, Chen G, Chen H, Hu Y, Niu J, Ding Y. (2019)
Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial.
Pharmazie, 74 (11): 688-693. [PMID:31739839]
3. Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H et al.. (2021)
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
J Clin Oncol, 39 (27): 3002-3011. [PMID:34185551]
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al.. (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res, 64 (19): 7099-109. [PMID:15466206]